Commentary
Pathogenesis of rheumatoid arthritis: how early is early?
Gary S Firestein

Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA

Corresponding author: Gary S Firestein, gfirestein@ucsd.edu

Published: 17 June 2005
Arthritis Research & Therapy 2005, 7:157-159 (DOI 10.1186/ar1780)

Abstract

Studies of cytokine expression in rheumatoid arthritis have provided key insights into the pathogenesis of disease and have offered clues for effective therapy. Patterns of T-cell products in chronic rheumatoid synovitis suggest that T helper type 1 cells contribute to the perpetuation of disease. However, there is no guarantee that the mechanisms of late disease are identical to very early rheumatoid arthritis. Evaluation of the cytokine profile at the earliest time points after onset of symptoms could identify novel targets that prevent progression to chronic arthritis.

Development of hypotheses to explain the pathogenesis of chronic rheumatoid arthritis (RA), including the interesting new study by Raza and colleagues [1], has been a wondrous adventure. Virtually every immune cell type and inflammatory mediator has been implicated in the disease process at one time or another. Older, temporarily discarded hypotheses on B cells and immune complexes have enjoyed renewed energy with the advent of anti-B-cell therapies [2]. Now that T-cell-directed approaches, such as CTLA4-Ig [3], demonstrate efficacy, it appears that therapies targeting this cell lineage also are effective in a subpopulation of patients. Hence, chronic rheumatoid synovitis is marked by a complex interplay between multiple cell types, and individual patients display their own distinct hierarchy for the efficacy of therapeutic interventions [4].

On the other hand, there is much less information on disease mechanisms in the earliest stages of RA. This is, in part, due to the changing definitions of ‘early RA’, with a cutoff that has gradually migrated from 2 years of symptoms to as little as 6 weeks. Even in the latter case, a prolonged preclinical period of immune hyper-reactivity and asymptomatic synovitis could exist before the disease becomes fully established. Many investigators believe that an appropriate genetic background in combination with stochastic events, such as activation of innate immunity, can serve as the trigger for RA.

Subsequent perpetuation of the disease might involve entirely distinct adaptive immune mechanisms that are independent of the initiating events.

Implicit in this assessment, an adaptive T-cell response might be required for full expression of RA. The nature of this response remains poorly defined, and studies of chronic rheumatoid synovitis have generally demonstrated blunted T-cell function and surprisingly limited cytokine production compared with other T-cell-mediated diseases. The lymphocyte cytokine profile in chronic RA synovium and surface chemokine receptor display is most consistent with a T helper cell type 1 (Th1)-driven disease [5]. This cell type plays a key role in the pathogenesis of many rodent models of arthritis, including collagen-induced arthritis, antigen-induced arthritis, and adjuvant arthritis, where Th1 cytokines generally predominate early and T helper cell type 2 (Th2) factors contribute to the resolution. In this context, the study by Raza and colleagues raises questions about the role of T cells in RA and other forms of inflammatory arthritis.

Many studies have suggested that ‘chronic’ RA and ‘early’ RA have more similarities than differences [6]. Histopathologic evaluation of synovial tissue shows chronic changes shortly after the onset of symptoms, and the cytokine profile in early disease as determined by immunohistochemistry is nearly identical to long-standing RA [7-9]. The latter finding was based on patients with up to 1 year of disease, but some patients with synovitis for as little as 2 months were included in the analysis. Asymptomatic joints in patients with RA also have very similar profiles to chronic RA, albeit with fewer synovial macrophages and less immunoreactive IL-8 [10]. These data suggest either that the mechanisms of RA in early disease are the same as in late arthritis or that the window of obvious T-cell activation needs to be pushed even earlier, perhaps to the preclinical phase.

IFN-γ = interferon gamma; IL = interleukin; RA = rheumatoid arthritis; Th = T helper cell.
The present study demonstrating T-cell cytokines in the first few months of disease might provide some insights into the time frame of T-cell activation in early RA. The data suggest that T-cell cytokines might be abundant in the first 3 months but that the levels later drift downward and are eventually undetectable. However, there are some discrepancies with many previous reports that remain unexplained. For instance, IL-4 and IL-13 (both classic Th2 cytokines) but not interferon gamma (IFN-γ) were detected early in RA, thereby making it difficult to call RA a ‘Th1’-mediated disease. In contrast, seronegative spondyloarthropathies had high IFN-γ, which is the opposite of the ‘Th2’ pattern observed in chronic disease [11]. The absence of IFN-γ in synovial effusions of patients with chronic RA contrasts with other studies, including our experiments over 15 years ago when we were impressed by surprisingly low IFN-γ concentrations [12]. Although the levels are below the amount required to induce HLA-DR on monocytes, detectable amounts were clearly identified in synovial effusions. Other cytokines previously reported in chronic RA, such as granulocyte–macrophage colony-stimulating factor and IL-17, were not detected with the multiplex system employed by the authors [13,14]. In contrast to previous studies, the levels of IL-15 were similar in chronic RA and osteoarthritis synovial effusions [15].

The authors also comment on a potential role of stromal-derived cytokines and growth factors in early RA and late RA. Compared with the lengthy list of T-cell products and macrophage products, the array of mesenchymal cell products evaluated was more limited. Additional information on key cytokines such as stromal derived factor 1, transforming growth factor beta, and the bone morphogenic proteins would be useful, even if individual immunoassays are required to quantify these data [16,17].

Many of the differences with previous studies are difficult to resolve and could be due to concomitant medications or other confounding technical influences. The use of multiplex assay systems is relatively new, and the correlations with standard single analyte assays of complex body fluids would be helpful to assess precision and accuracy. The authors did perform several careful studies that appeared to rule out interference by rheumatoid factors, although validation to evaluate the effect of other synovial fluid constituents on multiplex analysis and the antibody pairs is very important. Antibody pairs validated for tissue culture supernatants or blood do not confirmatory studies to evaluate the cytokine profile in early synovitis are essential to resolve the differences with previous work. If validated, a careful reassessment of Th1/Th2 balance in early RA and late RA would be important.

Conclusions
Although data implicating Th2 cytokines in early arthritis differ from our expectations, this information might influence our concepts of how RA evolves. In light of the possible technical issues related to multiplex analysis, confirmatory studies to evaluate the cytokine profile in early synovitis are essential to resolve the differences with previous work. If validated, a careful reassessment of Th1/Th2 balance in early RA and late RA would be important.

Competing interests
The author(s) declare that they have no competing interests.

References
1. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M: Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Research & Therapy 2005, 7:R784-R795.
2. Edwards JC, Szczepanski L, Szczepanski J, Filippowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
3. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuaamah IF, et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
4. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
5. Miossec P, van den Berg W: Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997, 40:2105-2115.
6. Tak PP: Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001, 15:17-26.
7. Kraan MC, Haringman JJ, Post WJ, Versendaal J, Breedveld FC, Tak PP: Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford) 1999, 38:1074-1080.
8. Katrbić A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, Kraan MC, Youssef PP: Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:988-994.
9. Smeets TJ, Dolhain RJEM, Miltenburg AM, de Kuiper R, Breedveld FC, Tak PP: Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue. Clin Immunol Immunopathol 1999, 88:84-90.
10. Kraan MC, Patel DD, Haringman JJ, Smith MD, Weendon H, Ahern MJ, Breedveld FC, Tak PP: The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 2001, 3:65-71.
11. Simon AK, Seippelt E, Sieper J: Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994, 91:8962-8966.
12. Firestein GS, Zvaifler NJ: Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum 1987, 30:864-871.

13. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ: Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 1989, 83:876-882.

14. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.

15. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, Sturrock RD, Wilkinson PC, Liew FY: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996, 2:175-182.

16. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Ginschick HJ, Yavuz S, Lipsky PE: Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000, 165:6590-6598.

17. Lories RJ, Derese I, Ceuppens JL, Luyten FP: Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 2003, 48:2807-2818.

18. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27-35.

19. Tak PP, van der Lubbe PA, Cauil A, Daha MR, Smeets TJ, Kluin PM, Meinders AE, Yanni G, Panayi GS, Breedveld FC: Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995, 38:1457-1465.